International Journal of Cardiology
Volume 135, Issue 2 , Pages 184-186, 26 June 2009

Secondary prevention of coronary artery disease in urban Indian primary care

Department of Medicine, Monilek Hospital and Research Center, Sector-4, Jawahar Nagar, Jaipur, 302004, Rajasthan, India

Received 30 April 2007; received in revised form 22 January 2008; accepted 29 March 2008. published online 14 July 2008.

Abstract 

Background

Although secondary prevention has the potential to substantially reduce the risk of coronary events, its impact depends on the extent to which it is applied in the community. Presently, there is no information on the frequency with which drugs recommended for secondary prevention of CAD are used in the setting of primary care in India or other developing countries. Such information could help focus attention of physicians on its importance.

Method

In a prospective epidemiologic survey, 134 primary care physicians from 50 randomly selected cities distributed throughout India identified outpatients with stable CAD and symptoms of angina. Demographic and clinical characteristics, together with their treatment were recorded on a standardized questionnaire.

Results

In 406 patients, the number (%, 95% CI) receiving aspirin was, 335 (82.5, 78.2 to 86.2); b-blockers, 215 (53.0, 48.1 to 57.9); angiotensin converting enzyme inhibitors (ACEI), 63 (15.5, 12.0 to 19.0); and statins, 280 (69.0, 61.0 to 77.0). Hypertension was untreated in 125 patients (33.4, 28.6 to 38.2). Combination treatment with any two (of aspirin, b-blocker, statin, ACEI, or antihypertensive agent other than b-blocker and ACEI) was received by 249 patients (61.3, 51.3 to 71.3); and with any three by 21 (5.2, 3.0 to 7.3).

Discussion

Secondary prevention is under utilized in Indian patents with CAD. Against the background of an emerging epidemic, physicians in primary care need to increase the use of widely available specific secondary preventive agents recommended by guidelines.

Keywords: Secondary prevention, Coronary artery disease, Epidemiology, India

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Disclosure: The study was supported by a financial grant from Serdia Pharmaceuticals (India) Pvt. Ltd., the manufacturers of perindopril to cover organizational expenses. No other financial consideration was involved, and the authors have no potential conflict of interest to declare.

PII: S0167-5273(08)00513-5

doi:10.1016/j.ijcard.2008.03.047

International Journal of Cardiology
Volume 135, Issue 2 , Pages 184-186, 26 June 2009